To accurately assess liver damage in patients with EPP with hyperbilirubinemia, we recommend a thorough evaluation of OATP1B1/1B3 function by analyzing genetic polymorphisms and reviewing their history of exposure to OATP1B1/1B3 inhibitors. Here, SLCO1B1 is linked to Hyperbilirubinemia.